Tissue kallikrein, blood pressure regulation, and hypertension: Insight from genetic kallikrein deficiency

Biological Chemistry

Volumn 394, Issue 3, 2013, Pages 329-333

  Potier, Louis ^a,b,c   Waeckel, Ludovic ^a,b,c   Richer, Christine ^a,b,c   Roussel, Ronan ^a,b,c   Bouby, Nadine ^a,b,c   Alhenc Gelas, Francois ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

bradykinin; epithelial sodium channel; hyperaldosteronism; renal artery obstruction; sodium retention; transgenic mice

Indexed keywords

TISSUE KALLIKREIN;

BLOOD PRESSURE REGULATION; ENZYME DEFICIENCY; GENETIC MODEL; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; REVIEW; SODIUM RETENTION;

ANIMALS; BLOOD PRESSURE; HUMANS; HYPERTENSION; MICE; MICE, TRANSGENIC; TISSUE KALLIKREINS;

ANIMALIA; MURINAE; MUS; MUS MUSCULUS;

EID: 84876581241     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/hsz-2012-0332     Document Type: Review

References (39)

1. Abelous, J.E. and Bardier, E. (1909). Les substances hypotensives de l'urine humaine normale. C. R. Soc. Biol. 66, 511-520.
2. Ader, J.L., Tran-Van, T., and Praddaude, F. (1988). Renal tissue kallikrein in newborn and young SHR. Am. J. Hypertens. 1, 53S- 55S.
3. Alfie, M.E., Yang, X.P., Hess, F., and Carretero, O.A. (1996). Salt-sensitive hypertension in bradykinin B2 receptor knockout mice. Biochem. Biophys. Res. Commun. 224, 625-630.
4. Azizi, M., Boutouyrie, P., Bissery, A., Agharazii, M., Verbeke, F., Stern, N., Bura-Riviere, A., Laurent, S., Alhenc-Gelas, F., and Jeunemaitre, X. (2005). Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans. J. Clin. Invest. 115, 780-787.
5. Azizi, M., Emanueli, C., Peyrard, S., Maddedu, P., Alhenc-Gelas, F., and Campbell, D.J. (2008). Genetic and dietary control of plasma tissue kallikrein secretion and urinary kinins exretion in man. J. Hypertens. 26, 714-720.
6. Bergaya, S., Meneton, P., Bloch-Faure, M., Mathieu, E., Alhenc-Gelas, F., Levy, B.I., and Boulanger, C.M. (2001). Decreased flow-dependent dilation in carotid arteries of tissue kallikreinknockout mice. Circ. Res. 88, 593-599.
7. Bergaya, S., Hilgers, R.H., Meneton, P., Dong, Y., Bloch-Faure, M., Inagami, T., Alhenc-Gelas, F., Levy, B.I., and Boulanger, C.M. (2004). Flow-dependent dilation mediated by endogenous kinins requires angiotensin AT2 receptors. Circ. Res. 94, 1623-1629.
8. Berry, T.D., Hasstedt, S.J., Hunt, S.C., Wu, L.L., Smith, J.B., Ash, K.O., Kuida, H., and Williams, R.R. (1989). A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension 13, 3-8.
9. Bodin, S., Chollet, C., Goncalves-Mendes, N., Gardes, J., Pean, F., Heudes, D., Bruneval, P., Marre, M., Alhenc-Gelas, F., and Bouby, N. (2009). Kallikrein protects against microalbuminuria in experimental type I diabetes. Kidney Int. 76, 395-403.
10. Carretero, O. and Scicli, A. (1995). The kallikrein-kinin system as a regulator of cardiovascular and renal function. In: Hypertension: Pathophysiology, Diagnosis, and Management, J.H. Laragh and B.M. Brenner, eds. (New York: Raven Press), pp. 983-999.
11. Dedio, J., Wiemer, G., Rutten, H., Dendorfer, A., Scholkens, B.A., Muller-Esterl, W., and Wohlfart, P. (2001). Tissue kallikrein KLK1 is expressed de novo in endothelial cells and mediates relaxation of human umbilical veins. Biol. Chem. 382, 1483-1490.
12. Elliot, A.H. and Nuzum, F.R. (1934). The urinary excretion of a depressor substance (kallikrein of Frey and Kraut) in arterial hypertension. Endocrinology 18, 462-474.
13. Frey, E.K. and Kraut, H. (1926). Ü ber einen von der Niere ausgeschiedenen, die Herzt ä tigkeit anregenden Stoff. Hoppe-Seyler's Z. Physiol. Chem. 157, 32-36.
14. Griol-Charhbili, V., Sabbah, L., Colucci, J., Vincent, M.P., Baudrie, V., Laude, D., Elghozi, J.L., Bruneval, P., Picard, N., Meneton, P., et al. (2009). Tissue kallikrein deficiency and renovascular hypertension in the mouse. Am. J. Physiol. Regul. Integr. Comp. Physiol. 296, R1385- R1391.
15. Hecquet, C., Tan, F., Marcic, B.M., and Erdos, E.G. (2000). Human bradykinin B(2) receptor is activated by kallikrein and other serine proteases. Mol. Pharmacol. 58, 828-836.
16. Huang, W., Gallois, Y., Bouby, N., Bruneval, P., Heudes, D., Belair, M.F., Krege, J.H., Meneton, P., Marre, M., Smithies, O., et al. (2001). Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc. Natl. Acad. Sci. USA 98, 13330-13334.
17. Kakoki, M. and Smithies, O. (2009). The kallikrein-kinin system in health and in diseases of the kidney. Kidney Int. 75, 1019-1030.
18. Kraut, H., Frey, E.K., and Werle, E. (1930). Ü ber die Inaktivierung des Kallikreins. Hoppe-Seyler's Z. Physiol. Chem. 192, 1-21.
19. Marchetti, J., Imbert-Teboul, M., Alhenc-Gelas, F., Allegrini, J., Menard, J., and Morel, F. (1984). Kallikrein along the rabbit microdissected nephron: A micromethod for its measurement. Effect of adrenalectomy and DOCA treatment. Pfl ü ger's Arch. 401, 27-33.
20. Margolius, H.S., Geller, R.G., De Jong, W., Pisano, J.J., and Sjoerdsma, A. (1972). Urinary kallikrein excretion in hypertension. Circ. Res. 31, 125-131.
21. Margolius, H.S., Horwitz, D., Geller, R.G., Alexander, R.W., Gill, J.R., Jr., Pisano, J.J., and Keiser, H.R. (1974). Urinary kallikrein excretion in normal man. Relationships to sodium intake and sodium-retaining steroids. Circ. Res. 35, 812-819.
22. Margolius, H.S., Horwitz, D., Pisano, J.J., and Keiser, H.R. (1976). Relationships among urinary kallikrein, mineralocorticoids and human hypertensive disease. Fed. Proc. 35, 203-206.
23. Marre, M., Jeunemaitre, X., Gallois, Y., Rodier, M., Chatellier, G., Sert, C., Dusselier, L., Kahal, Z., Chaillous, L., Halimi, S., et al. (1997). Contribution of genetic polymorphism in the reninangiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. J. Clin. Invest. 99, 1585-1595.
24. Meneton, P., Bloch-Faure, M., Hagege, A.A., Ruetten, H., Huang, W., Bergaya, S., Ceiler, D., Gehring, D., Martins, I., Salmon, G., et al. (2001). Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice. Proc. Natl. Acad. Sci. USA 98, 2634-2639.
25. Picard, N., Eladari, D., El Moghrabi, S., Planes, C., Bourgeois, S., Houillier, P., Wang, Q., Burnier, M., Deschenes, G., Knepper, M.A., et al. (2008). Defective ENaC processing and function in tissue kallikrein-deficient mice. J. Biol. Chem. 283, 4602-4611.
26. Pizard, A., Richer, C., Bouby, N., Picard, N., Meneton, P., Azizi, M., and Alhenc-Gelas, F. (2008). Genetic deficiency in tissue kallikrein activity in mouse and man: Effect on arteries, heart and kidney. Biol. Chem. 389, 701-706.
27. Pratt, J.H. (2005). Central role for ENaC in development of hypertension. J. Am. Soc. Nephrol. 16, 3154-3159.
28. Pravenec, M., Kren, V., Kunes, J., Scicli, A.G., Carretero, O.A., Simonet, L., and Kurtz, T.W. (1991). Cosegregation of blood pressure with a kallikrein gene family polymorphism. Hypertension 17, 242-246.
29. Rapp, J.P., Joseph, M.K., and McPartland, R.P. (1982). Proteins binding to kallikrein and esterase A2 in the urine of salt-sensitive and salt-resistant rats. Hypertension 4, 545-555.
30. Seino, M., Abe, K., Sakurai, Y., Irokawa, N., Yasujima, M., Chiba, S., Otsuka, Y., and Yoshinaga, K. (1977). Effect of spironolactone on urinary kallikrein excretion in patients with essential hypertension and in primary aldosteronism. Tohoku J. Exp. Med. 121, 111-119.
31. Silva, J.A., Jr., Araujo, R.C., Baltatu, O., Oliveira, S.M., Tschope, C., Fink, E., Hoffmann, S., Plehm, R., Chai, K.X., Chao, L., et al. (2000). Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene. FASEB J. 14, 1858-1860.
32. Slim, R., Torremocha, F., Moreau, T., Pizard, A., Hunt, S.C., Vuagnat, A., Williams, G.H., Gauthier, F., Jeunemaitre, X., and Alhenc-Gelas, F. (2002). Loss-of-function polymorphism of the human kallikrein gene with reduced urinary kallikrein activity. J. Am. Soc. Nephrol. 13, 968-976.
33. Trabold, F., Pons, S., Hagege, A.A., Bloch-Faure, M., Alhenc-Gelas, F., Giudicelli, J.F., Richer-Giudicelli, C., and Meneton, P. (2002). Cardiovascular phenotypes of kinin B2 receptor- and tissue kallikrein-deficient mice. Hypertension 40, 90-95.
34. Waeckel, L., Potier, L., Chollet, C., Taveau, C., Bruneval, P., Roussel, R., Alhenc-Gelas, F., and Bouby, N. (2012). Antihypertensive role of tissue kallikrein in hyperaldosteronism in the mouse. Endocrinology 153, 3886-3896.
35. Wang, J., Xiong, W., Yang, Z., Davis, T., Dewey, M.J., Chao, J., and Chao, L. (1994). Human tissue kallikrein induces hypotension in transgenic mice. Hypertension 23, 236-243.
36. Ward, R. (1990). Familial aggregation and genetic epidemiology of blood pressure. In: Hypertension: Pathophysiology, Diagnosis and Management, J.H. Laragh and B.M. Brenner, eds. (New York: Raven Press), pp. 81-100.
37. Yu, H., Song, Q., Freedman, B.I., Chao, J., Chao, L., Rich, S.S., and Bowden, D.W. (2002). Association of the tissue kallikrein gene promoter with ESRD and hypertension. Kidney Int. 61, 1030-1039.
38. Zinner, S.H., Margolius, H.S., Rosner, B., Keiser, H.R., and Kass, E.H. (1976). Familial aggregation of urinary kallikrein concentration in childhood: Relation to blood pressure, race and urinary electrolytes. Am. J. Epidemiol. 104, 124-132.
39. Zinner, S.H., Margolius, H.S., Rosner, B., and Kass, E.H. (1978). Stability of blood pressure rank and urinary kallikrein concentration in childhood: An eight-year follow-up. Circulation 58, 908-915.